SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Dexcom Inc. – ‘8-K’ for 7/26/22

On:  Thursday, 7/28/22, at 4:23pm ET   ·   For:  7/26/22   ·   Accession #:  1093557-22-145   ·   File #:  0-51222

Previous ‘8-K’:  ‘8-K’ on / for 7/28/22   ·   Next:  ‘8-K’ on 8/5/22 for 8/1/22   ·   Latest:  ‘8-K’ on / for 4/25/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 7/28/22  Dexcom Inc.                       8-K:8       7/26/22   10:365K

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     34K 
 5: R1          Cover Page                                          HTML     45K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- dxcm-20220726_htm                   XML     21K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- dxcm-20220726_lab                     XML     67K 
 4: EX-101.PRE  XBRL Presentations -- dxcm-20220726_pre              XML     33K 
 2: EX-101.SCH  XBRL Schema -- dxcm-20220726                         XSD     10K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    16K 
10: ZIP         XBRL Zipped Folder -- 0001093557-22-000145-xbrl      Zip    107K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C: 
  dxcm-20220726  
 i false i 000109355700010935572022-07-262022-07-26

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM  i 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):  i July 26, 2022
dxcm-20220726_g1.jpg
 i DEXCOM, INC.
(Exact Name of the Registrant as Specified in Its Charter)

 i Delaware i 000-51222 i 33-0857544
(State or Other Jurisdiction of Incorporation or Organization)(Commission File Number)(I.R.S. Employer Identification No.)
 i 6340 Sequence Drive,  i San Diego,  i CA  i 92121
(Address of Principal Executive Offices, Including Zip Code)
( i 858)  i 200-0200
(Registrant’s Telephone Number, Including Area Code)
(Former Name, Former Address, and Former Fiscal Year, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 i Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
 i Common Stock, $0.001 Par Value Per Share i DXCM i Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
 i 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 




ITEM 8.01.
OTHER EVENTS.
On July 26, 2022, a duly authorized committee of our Board of Directors authorized and approved a share repurchase program of up to $700 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2023 (the “Share Repurchase Program”).

Repurchases of our common stock under the Share Repurchase Program may be made from time to time, on the open market, in privately negotiated transactions or by other methods, at our discretion, and in accordance with the limitations set forth in Rule 10b-18 promulgated under the Securities Exchange Act of 1934, as amended, and other applicable federal and state laws and regulations. The timing of any repurchases will depend on market conditions and will be made at our discretion.

The Share Repurchase Program does not obligate us to repurchase any dollar amount or number of shares, and the program may be extended, modified, suspended, or discontinued at any time.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DEXCOM, INC.
By: 
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
Date:


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
6/30/23
Filed on:7/28/228-K
For Period end:7/26/22
 List all Filings 
Top
Filing Submission 0001093557-22-000145   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 3:02:36.1am ET